468 related articles for article (PubMed ID: 8094248)
1. Helminth infection results in decreased virus-specific CD8+ cytotoxic T-cell and Th1 cytokine responses as well as delayed virus clearance.
Actor JK; Shirai M; Kullberg MC; Buller RM; Sher A; Berzofsky JA
Proc Natl Acad Sci U S A; 1993 Feb; 90(3):948-52. PubMed ID: 8094248
[TBL] [Abstract][Full Text] [Related]
2. Increased susceptibility of mice infected with Schistosoma mansoni to recombinant vaccinia virus: association of viral persistence with egg granuloma formation.
Actor JK; Marshall MA; Eltoum IA; Buller RM; Berzofsky JA; Sher A
Eur J Immunol; 1994 Dec; 24(12):3050-6. PubMed ID: 7805733
[TBL] [Abstract][Full Text] [Related]
3. Brucella abortus conjugated with a peptide derived from the V3 loop of human immunodeficiency virus (HIV) type 1 induces HIV-specific cytotoxic T-cell responses in normal and in CD4+ cell-depleted BALB/c mice.
Lapham C; Golding B; Inman J; Blackburn R; Manischewitz J; Highet P; Golding H
J Virol; 1996 May; 70(5):3084-92. PubMed ID: 8627787
[TBL] [Abstract][Full Text] [Related]
4. A vaccinia-gp160-based vaccine but not a gp160 protein vaccine elicits anti-gp160 cytotoxic T lymphocytes in some HIV-1 seronegative vaccinees.
Perales MA; Schwartz DH; Fabry JA; Lieberman J
J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Sep; 10(1):27-35. PubMed ID: 7648281
[TBL] [Abstract][Full Text] [Related]
5. Induction of a major histocompatibility complex class I-restricted cytotoxic T-lymphocyte response to a highly conserved region of human immunodeficiency virus type 1 (HIV-1) gp120 in seronegative humans immunized with a candidate HIV-1 vaccine.
Johnson RP; Hammond SA; Trocha A; Siliciano RF; Walker BD
J Virol; 1994 May; 68(5):3145-53. PubMed ID: 7908700
[TBL] [Abstract][Full Text] [Related]
6. Persistent infection by Helicobacter pylori down-modulates virus-specific CD8+ cytotoxic T cell response and prolongs viral infection.
Shirai M; Arichi T; Nakazawa T; Berzofsky JA
J Infect Dis; 1998 Jan; 177(1):72-80. PubMed ID: 9419172
[TBL] [Abstract][Full Text] [Related]
7. An HIV-1 envelope protein vaccine elicits a functionally complex human CD4+ T cell response that includes cytolytic T lymphocytes.
Stanhope PE; Liu AY; Pavlat W; Pitha PM; Clements ML; Siliciano RF
J Immunol; 1993 May; 150(10):4672-86. PubMed ID: 8097759
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of human immunodeficiency virus (HIV)-specific CD4+ and CD8+ cytotoxic T-lymphocyte activities in HIV-infected asymptomatic patients given recombinant gp160 vaccine.
Kundu SK; Katzenstein D; Moses LE; Merigan TC
Proc Natl Acad Sci U S A; 1992 Dec; 89(23):11204-8. PubMed ID: 1360665
[TBL] [Abstract][Full Text] [Related]
9. Comparative clonal analysis of human immunodeficiency virus type 1 (HIV-1)-specific CD4+ and CD8+ cytolytic T lymphocytes isolated from seronegative humans immunized with candidate HIV-1 vaccines.
Hammond SA; Bollinger RC; Stanhope PE; Quinn TC; Schwartz D; Clements ML; Siliciano RF
J Exp Med; 1992 Dec; 176(6):1531-42. PubMed ID: 1460417
[TBL] [Abstract][Full Text] [Related]
10. Induction of CD8+ cytotoxic T lymphocytes by immunization with syngeneic irradiated HIV-1 envelope derived peptide-pulsed dendritic cells.
Takahashi H; Nakagawa Y; Yokomuro K; Berzofsky JA
Int Immunol; 1993 Aug; 5(8):849-57. PubMed ID: 8398980
[TBL] [Abstract][Full Text] [Related]
11. Cross-clade envelope glycoprotein 160-specific CD8+ cytotoxic T lymphocyte responses in early HIV type 1 clade B infection.
Wilson SE; Pedersen SL; Kunich JC; Wilkins VL; Mann DL; Mazzara GP; Tartaglia J; Celum CL; Sheppard HW
AIDS Res Hum Retroviruses; 1998 Jul; 14(11):925-37. PubMed ID: 9686639
[TBL] [Abstract][Full Text] [Related]
12. Quantitative analysis of the human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: differential CTL responses to HIV-1 and Epstein-Barr virus in late disease.
Carmichael A; Jin X; Sissons P; Borysiewicz L
J Exp Med; 1993 Feb; 177(2):249-56. PubMed ID: 8093890
[TBL] [Abstract][Full Text] [Related]
13. Persisting human immunodeficiency virus type 1 gp160-specific human T lymphocyte responses including CD8+ cytotoxic activity after receipt of envelope vaccines.
el-Daher N; Keefer MC; Reichman RC; Dolin R; Roberts NJ
J Infect Dis; 1993 Aug; 168(2):306-13. PubMed ID: 8335968
[TBL] [Abstract][Full Text] [Related]
14. Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein.
Cooney EL; McElrath MJ; Corey L; Hu SL; Collier AC; Arditti D; Hoffman M; Coombs RW; Smith GE; Greenberg PD
Proc Natl Acad Sci U S A; 1993 Mar; 90(5):1882-6. PubMed ID: 8446603
[TBL] [Abstract][Full Text] [Related]
15. Helper-cytotoxic T lymphocyte (CTL) determinant linkage required for priming of anti-HIV CD8+ CTL in vivo with peptide vaccine constructs.
Shirai M; Pendleton CD; Ahlers J; Takeshita T; Newman M; Berzofsky JA
J Immunol; 1994 Jan; 152(2):549-56. PubMed ID: 8283036
[TBL] [Abstract][Full Text] [Related]
16. Cross-reactive lysis of human targets infected with prototypic and clinical human immunodeficiency virus type 1 (HIV-1) strains by murine anti-HIV-1 IIIB env-specific cytotoxic T lymphocytes.
Chada S; DeJesus CE; Townsend K; Lee WT; Laube L; Jolly DJ; Chang SM; Warner JF
J Virol; 1993 Jun; 67(6):3409-17. PubMed ID: 8497058
[TBL] [Abstract][Full Text] [Related]
17. IL-12 delivery from recombinant vaccinia virus attenuates the vector and enhances the cellular immune response against HIV-1 Env in a dose-dependent manner.
Gherardi MM; Ramirez JC; Rodríguez D; Rodríguez JR; Sano G; Zavala F; Esteban M
J Immunol; 1999 Jun; 162(11):6724-33. PubMed ID: 10352291
[TBL] [Abstract][Full Text] [Related]
18. Recombinant vaccinia virus-induced T-cell immunity: quantitation of the response to the virus vector and the foreign epitope.
Harrington LE; Most Rv Rv; Whitton JL; Ahmed R
J Virol; 2002 Apr; 76(7):3329-37. PubMed ID: 11884558
[TBL] [Abstract][Full Text] [Related]
19. Mice infected with Schistosoma mansoni develop a novel non-T-lymphocyte suppressor population which inhibits virus-specific CTL induction via a soluble factor.
Marshall MA; Jankovic D; Maher VE; Sher A; Berzofsky JA
Microbes Infect; 2001 Nov; 3(13):1051-61. PubMed ID: 11709285
[TBL] [Abstract][Full Text] [Related]
20. Schistosomal egg antigen-responsive CD8 T-cell population in Schistosoma mansoni-infected BALB/c mice.
Pancré V; Delacre M; Herno J; Auriault C
Immunology; 1999 Dec; 98(4):525-34. PubMed ID: 10594684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
